A Randomized, Double-blind, Placebo-controlled, Multi-center, Phase 3 Study to Evaluate the Efficacy and Safety of MEDOTIXN in Subject With Benign Masseteric Hypertrophy
Phase of Trial: Phase III
Latest Information Update: 01 Apr 2019
Price : $35 *
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Hypertrophy; Muscular disorders
- Focus Therapeutic Use
- Sponsors Medytox
- 25 Mar 2019 Planned End Date changed from 1 May 2019 to 31 Dec 2019.
- 25 Mar 2019 Planned primary completion date changed from 1 Aug 2018 to 31 Aug 2019.
- 25 Mar 2019 Status changed from not yet recruiting to recruiting.